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Abstract 
Purpose: Most cancer data sources lack information on an important outcome: metastatic 
recurrence. Electronic medical records (EMRs) and population-based cancer registries contain 
complementary information on cancer outcomes and treatment, yet are rarely used 
synergistically. To enable detection of metastatic breast cancer (MBC) recurrence, we applied a 
semi-supervised machine learning framework to linked EMR-California Cancer Registry (CCR) 
data.  
Patients and Methods:  We studied 11,459 female patients who received an incident breast 
cancer diagnosis from 2000-2014 and were treated at Stanford Health Care.  The dataset 
consisted of structured data and unstructured free-text clinical notes from each patient’s EMR, 
linked to the population-based CCR, a component of the Surveillance, Epidemiology and End 
Results (SEER) database. We extracted information on metastatic disease from patient notes to 
infer a class label and then trained a logistic regression model with regularization for metastatic 
recurrence classification.  We evaluated model performance on an oncologist-labeled set of 146 
patients. 
Results: Among 11,459 patients studied, 495 (4.3%) had de novo stage IV MBC. Of the 
remaining 10,964 patients with Stage 0-III disease, 1,374 (12.5%) were classified as having 
recurrent MBC and 9,590 (87.5%) were classified as not having MBC. The median follow-up 
time is 96.3 months (mean 97.8, standard deviation 46.7). The best-performing model 
incorporated natural language processing of EMR-derived features with CCR-derived features 
and had an area under the receiver-operating characteristic curve=0.925 [95% confidence 
interval: 0.880-0.969], sensitivity=0.861, specificity=0.878 and overall accuracy=0.870. 
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Conclusion: A framework for MBC case detection combining EMR and SEER registry data 
achieved good sensitivity, specificity and discrimination without requiring expert-labeled 
examples. This approach enables population-based research on how patients die from cancer 
and may identify novel predictors of cancer recurrence. 
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Introduction 
More than 3.5 million Americans are living with breast cancer, of whom 41,070 (40,610 women 
and 460 men) died from the disease in 2017 (1). Despite substantial improvements in the 
treatment and prognosis of early-stage breast cancer, little is known about changes in survival 
and other outcomes of metastatic breast cancer (MBC) patients (2,3). MBC can be found at 
initial diagnosis (de novo Stage IV disease) or as a distant recurrence of the primary tumor. 
Electronic medical records (EMR) contain large amounts of data collected during routine 
medical care delivery and have the potential to generate practice-based evidence. However, it 
has been challenging to make use of this abundance of data in part because of difficulties in 
identifying which breast cancer patients have had metastatic recurrence (4). Although de novo 
MBC patients are followed by population-based cancer registries such as the California Cancer 
Registry (CCR) of the national Surveillance, Epidemiology and End Results (SEER) program of 
National Cancer Institute, de novo MBC represents approximately only a quarter of all 
metastatic patients (5,6). SEER registries are funded to record only the first few months of 
treatment, and continuous follow-up by any registry to assess for metastatic recurrence would 
be costly. Thus, there is a profound gap in our knowledge about treatment of MBC and how 
patients die of this disease.   
 
Manual case detection to identify metastatic cohorts is prohibitively laborious. An informatics 
approach to bridge the knowledge gap would be to identify recurrent MBC patients 
retrospectively from administrative healthcare claims and EMRs, which contain large amounts 
of data collected during routine medical care delivery and have the potential to generate much 
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needed real-world evidence. Prior studies have developed rule-based approaches that use 
structured data such as qualifying diagnoses, procedures and drug codes (7–11). While such 
approaches are simple to replicate in a new dataset, their reliability is challenged by coding bias 
and differential coding practices. In addition, these approaches can suffer from low sensitivity 
(40%-60%), despite reasonable specificity (70%-90%) (8–10). A promising alternative is 
emerging systems that analyze unstructured clinical text in EMR and have shown higher 
sensitivity and specificity (12,13). However, their limitations include a high cost of initial 
development, difficulty in adapting to new systems, and most significantly, the requirement for 
a prohibitively large amount of manually annotated training data.  
 
We sought to develop a semi-supervised machine learning framework for automating MBC case 
detection with the potential to support population-level surveillance research across California 
and nationally. Semi-supervised machine learning comprises a class of supervised learning 
techniques that make use of unlabeled data to train machine learning models. It falls between 
unsupervised learning (no labeled training data) and supervised learning (completely labeled 
training data). It typically consists of pairing a small amount of labeled data with a large amount 
of unlabeled data -- or in the case of the method distant supervision, a distinct data source that 
can be used to label training examples automatically for supervised learning, in the absence of 
human-labeled training data.  By leveraging the complementary patient data contained in the 
EMR and in the California Cancer Registry, our methodological innovation extends the distant 
supervision paradigm described by Mintz et al. to the problem of MBC case detection (14–16).  
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Methods  
Data Source 
The Oncoshare breast cancer research database comprises a three-way data linkage at the 
patient level. It is an integration of retrospective EMRs of Stanford Health Care (SHC) and 
multiple sites of the Palo Alto Medical Foundation (PAMF) in Northern California, both linked to 
data from California Cancer Registry, a SEER registry (17,18). Only SHC patients were included in 
this study. Human Subjects approval for all research reported here was obtained from the 
Institutional Review Boards of Stanford University and the State of California.   
 
The structured EMR fields in Oncoshare’s clinical database include each patient’s diagnoses, 
procedures and drug orders. The unstructured EMR fields include free-text clinician notes such 
as medical and social histories, impressions, and visit summaries. The CCR contains detailed 
demographic information such as patient age, race/ethnicity, zip code and neighborhood 
characteristics, insurance and marital status, tumor characteristics at initial breast cancer 
diagnosis, and continually updated survival data which SEER obtains through linkage to the 
Social Security Death Master file and other national databases (17,18). 
 
For this study, we focused on 11,459 breast cancer patients treated at SHC from 2000-2014.  
Descriptive information on the study population appears in Supplementary Tables S1 and S2. 
Supplemental Table S1. Length of follow-up in days by survival status and tumor stage at initial 
diagnosis in Stanford Health Care patients. Survival status was collected by California Cancer 
Registry as of 2014-12-31 or any later follow-up of the specific patient.  Last follow-up date was 
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the latest date of the last follow-up from California Cancer Registry, 2014-12-31 and last 
encounter date in Stanford Health Care’ electronic medical record.  A flow chart that shows 
how patients were analyzed by our framework appears in Figure 1. Metastatic disease that was 
de novo Stage IV was directly retrieved from the CCR. Our informatics method focused on 
detecting cases of metastatic recurrence and thus included only patients initially diagnosed in 
Stages 0-III as recorded by the CCR.  
 
Creating an Expert-Reviewed “Gold Standard” Patient Set for Evaluation 
Two board-eligible medical oncologists (A.W.K. and J.L.C.) manually reviewed de-identified 
EMRs from 146 female breast cancer patients to create an evaluation set: these patients’ 
records were not used in the development of the statistical classifier. Without the knowledge of 
the underlying prevalence of MBC, a balanced set of patients were iteratively selected based on 
evidence of MBC (or lack of) from clinical notes. The oncologists determined the presence or 
absence of a metastatic recurrence in each patient’s medical record using clinical notes, 
radiology reports, and pathology reports in the EMR. The most common source of information 
on recurrence was the most recent medical oncology or radiation oncology visit note. If there 
was no such note, or if this note was written more than six months before the time of chart 
review or the patient's death and did not indicate MBC, then more recent notes from other 
clinical specialties, pathology reports and imaging reports were examined. If no evidence of 
MBC was found after review of all these sources, then the patient was labeled as not having 
recurrent MBC.   
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Distant Supervision of MBC Classification 
Our distant supervision framework exploits the Oncoshare EMR-CCR linkage.  In the absence of 
a large number of manually annotated cases, we used one data source from the linked data, 
EMR, to infer a class label for metastatic recurrence.  These class labels were then used to 
supervise the learning of a classification model using input variables from the other data 
source, CCR.  Our methodological innovation is to extend the distant supervision paradigm 
described by Mintz et al., which has been applied for over a decade in the development of 
general domain natural language processing (NLP) and information extraction tools, to clinical 
case detection (15). 
 
Step 1: Processing EMR Clinical Notes and Assigning Distant Labels 
In Step 1, we used NLP-derived features to label patients that were likely to have experienced a 
metastatic recurrence, based on free-text patient notes in the EMR. Specifically, we adapted an 
open-source clinical text analysis tool, CLEVER (CL-inical EV-ent R-ecognizer), which has been 
validated for EMR-based information extraction tasks in prior work, to extract metastatic 
disease information (19). This decision was based on the efficiency of CLEVER’s tagger, which 
facilitates the review of intermediate system output by subject matter experts and their 
inclusion in the development of custom clinical NLP extractors.  CLEVER’s source code, base 
terminology, and all customized components that were developed as part of this work are 
distributed publicly with a MIT software license on Github1. 
                                               
1 https://github.com/stamang/CLEVER 
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Although mature clinical NLP systems exist, they can be difficult to install and must be adapted 
to new sources of data. Simple taggers leveraging resources such as the National Library of 
Medicine’s Unified Medical Language System (UMLS) and SPECIALIST Lexicon tools have been 
shown to rival their performance and are easier to install (20). As illustrated in Supplementary 
Figure S4, CLEVER makes one modification to these types of general UMLS based taggers such 
as Noble Coder or MetaMap (21,22) in that we pre-trained word- and phrase-embedding 
models on clinical text to expand terminologies that are “seeded” by UMLS terms.  Using 
language-embedding models to identify new terms that were statistically similar to the high 
quality UMLS seed terms, we bootstrapped the development of an enhanced terminology using 
an iterative and incremental development process that included two informaticists and a 
subject matter expert to assist in the review of candidate terms.  
 
After our terminology for MBC information extraction was complete, we used CLEVER to 
annotate the corpus and extract mentions of different metastatic disease concepts that could 
be used to infer the presence or absence of a metastatic recurrence.  We also examined their 
immediate contexts to determine if the target term was negated, hypothetical or an attribute 
of a family member and not the patient (Supplementary Figure 5). Custom classes that we 
developed for metastatic recurrence detection are shown in Table 2.  The CLEVER rule that we 
developed to assign a case label to each patient was based on the positive present mention of a 
term from at least one of four custom word classes: “METSBONE”, “METSBRAIN”, “METSLIVER”, 
“METSLUNG”. These four word classes were constructed in a data-driven way from the most 
common sites of metastasis among our patients. In contrast to less specific word classes such as 
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“DRECUR”, which contains words and phrases that indicate a non-specific distant recurrence 
event, these four work classes include terms that indicate both metastatic disease and a 
location distant to the breast. 
 
Step 2: Recurrent MBC Classification 
In Step 2, we used the distant labels from Step 1 to train a metastatic recurrence classification 
model, integrating features from the CCR data. Structured fields used as input features of 
classification models included age, race, ethnicity, marital status, socioeconomic status, 
insurance type, comorbidity, year of initial breast cancer diagnosis, cancer stage, tumor grade, 
tumor histology, and tumor receptor status (e.g., expression of estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu)).  
Missing data in any of the structured features above were coded as a separate category. There 
were 427 patient-level features that were output from clinical text processing and were used as 
input features for patient classification.  We included the total number of terms mentioned in 
each of the customized word classes and their frequency as positive or negative concepts, in 
each specific note type and across all note types in the EMR. The NLP-derived features that 
were used to infer the distant label were excluded from this metastatic recurrence classification 
model, because they would result in “learning back” our inference process.  
 
We trained a logistic regression model with L2 regularization using glmnet package in R (23). 
Compared to regular logistic regression, L2 regularization smoothly shrinks regression 
coefficients based on regularization parameter, lambda, while retaining all input features in the 
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model (24). Such regularization can help reduce prediction error in our case because many of 
our input features are likely to be correlated. The probability cutoff of the classifier was chosen 
to optimize the F1 score. Finally, we tested our classifier on a physician-labeled set of 146 
patients (72 cases who had metastatic recurrence and 74 controls who did not have metastatic 
recurrence) and measured model performance using sensitivity, specificity, positive predictive 
value (PPV or precision), negative predictive value (NPV), and overall accuracy. In order to 
quantify the contribution of NLP-derived features in our classification model, we also trained an 
alternative classifier. Other than having different sets of input features, all aspects of the two 
classifiers were kept the same for fair comparisons. 
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Results 
Among the 11,459 patients, follow-up time ranged from 6.3 to 202.8 months with a median of 
96.3 months. The mean follow-up time was 97.8 months with a standard deviation 46.7 
months. There were 495 (4.3%) patients diagnosed with de novo Stage IV metastatic disease. In 
order to determine whether or not the rest of the patients had distant recurrences, we 
extracted additional metastatic disease information for each of the 8,892 patients who were 
stage 0-III at diagnosis and had at least one clinical note in the record.  Among these 8,892 
patients, our text mining step labeled 1,302 as having evidence of a metastatic recurrence 
(14.6%) and 7,590 as not having such evidence (85.4%). Using the test set of 146 manually 
annotated patients, our text processing step generated 15 false-positive and 8 false-negative 
labels, with an overall accuracy of 0.842 as shown in the first line of Table 3. 
 
Furthermore, we trained a distant supervised classification model for metastatic recurrence 
using these distantly labeled patients (1,302 as MBC and 7,590 not enough evidence of MBC) 
using a combination of CCR and NLP-derived features. A summary of all CCR features used in 
our classifier is listed in Table 1. Regularization parameter lambda was chosen to be 0.0451. 
Using 10-fold cross validation within the training data, we obtained the highest F-1 score of 
0.89 with a probability cut-off of 0.4. This cut-off was applied to be evaluated using the 146 
manually annotated records in the gold-standard set.  Our final classifier achieved an area 
under the receiver operating characteristic curve (AUC) of 0.925, with 95% confidence interval 
0.880-0.969 (DeLong) (Figure 2) (25).  There were 9 false-positives and 10 false-negatives, 
corresponding to sensitivity=0.861, specificity=0.878 and overall accuracy=0.870 (  
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Table 3). We benchmarked our classifier with one that includes only CCR features, keeping all 
other aspects of the classifier the same. We observed an improvement in all measurements as 
listed in third line of Table 3.  
 
Among 11,459 patients, 1,869 (16.3%) were MBC patients and 9,590 (83.7%) were classified as 
non-recurrent breast cancer patients. Among 1,869 MBC patients, 495 (26.5%) were de novo 
stage IV MBC patients, while 1,374 (73.5%) were classified as recurrent MBC patients (1,302 
from text processing step and 72 reviewed by physicians). This result is consistent with a recent 
report from the SEER registry using unrelated methods (6). Table 4 summarizes 
sociodemographic, clinical and genetic features of patients grouped into MBC (Stage 0-III at 
diagnosis), Stage IV at diagnosis, and non-MBC, based on our final metastatic recurrence 
classification model. The features with the highest beta coefficients from our statistical 
classifier are shown in Supplementary Table S3. 
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Discussion 
The lack of high-quality longitudinal databases that can be used to study metastatic recurrence 
is the biggest obstacle to practice-based evidence on how patients die from cancer.  To address 
this problem, we developed a novel scalable framework that enables retrospective MBC case 
detection with good performance. The contribution of this work is three-fold. First, we 
retrieved information from the unstructured text of clinical notes by developing a custom NLP 
extraction tool for metastatic recurrence. Second, we applied a semi-supervised machine 
learning technique, distant supervision, to the problem of metastatic recurrence classification.  
Lastly, we leveraged complementary data sources, specifically medical records from Stanford 
Health Care and the California Cancer Registry to develop a framework for detection of 
metastatic recurrence that can enable population-based studies of patients with metastatic 
cancer.  
 
Our classification model for recurrent MBC achieved good discriminating power and was based 
on a combination of features from both the CCR and EMRs. For each data source, the top 
predictors appear in Supplementary Table S3, by the relative rank of their model coefficient. 
While many of the strongest predictors from the CCR were known risk factors for metastatic 
recurrence (i.e., more advanced stage, triple negative disease, earlier year of diagnosis), one of 
the strongest classifying feature for distant recurrence was being uninsured. We found that 
patient insurance characteristics were essential for optimal classification of patients with 
metastatic disease, underscoring the importance of a diverse set of predictors and emphasizing 
the influence of healthcare access on cancer outcomes.  
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Our work suggests that an important next step is to develop tools for temporal information 
extraction.  Due to the relatively short time between metastatic recurrence and death, NLP 
approaches must perform at high accuracy to support meaningful survival analysis.  Although 
we initially planned to estimate onset time for metastatic recurrence cases, we found that 
simple methods (e.g., using the timestamp of a note with a positive-affirmative MBC mention) 
were not sufficient.  Analyses of notes from ten patients found that the most common errors of 
this naïve approach were attributable to phrases such as “patient was diagnosed with 
metastatic breast cancer [number] months ago at [another medical institute]”.  Possible future 
directions for automating recurrent MBC case detection could be to acquire linguistic 
annotations of English clinical text or other data for training a temporal metastatic recurrence 
classification model.  
 
Other limitations of this study include incomplete data due to patients receiving care outside of 
SHC; this is mitigated to some extent by statewide capture of treatment summaries by CCR but 
does not capture events outside of the state. Moreover, CCR is limited in treatment detail. 
Lastly, our work has primarily focused on NLP-derived features from unstructured free-text 
data in the EMR and structured data from the CCR.  The integration of structured data from the 
EMR, such as diagnoses, drugs and procedures that patients received as part of their treatment 
and continued survivorship care, may also improve classification, especially when there is 
ambiguity in describing metastasis in the notes or for patients without any clinical notes (12).  
Also, we used a relatively simple machine learning classifier: a generalized linear model. Use of 
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decision tree analysis and more nuanced machine learning methods may improve classification 
performance.  
 
In conclusion, we developed an open-source, machine learning MBC case detection framework 
that accurately labels breast cancer patients as metastatic or not using linked EMR-CCR data. 
Our final classifier for constructing MBC cohorts leveraged both EMR and SEER data and 
outperformed one that uses CCR features only.  As more linked datasets are developed (for 
example, the American Society of Clinical Oncology’s CancerLinQ initiative2), tools such as ours 
can readily be adapted for them. This approach has tremendous potential to identify cohorts of 
metastatic cancer patients and offer insights into the characteristics, care and outcomes of this 
important and understudied patient population. 
  
                                               
2 https://cancerlinq.org/ 
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Tables 
Table 1. Characteristics of all studied breast cancer patients (N=11,459) derived from the California Cancer Registry (26). 
 
Stage at Diagnosis 
Stage 0 Stage I Stage II Stage III Stage IV Missing 
No. % No. % No. % No. % No. % No. % 
Total 2335 100 3820 100 3443 100 1120 100 495 100 246 100 
Age at 
diagnosis: 
mean(std) 
55.31 (11.93) 56.68 (12.97) 53.26 (13.2) 51.77 (12.74) 54.61 (13.62) 56.71 (15.91) 
Year of breast cancer diagnosis 
Before 2005 586 25.10 1106 28.95 1137 33.02 245 21.88 116 23.43 75 30.49 
2005-2009 1039 44.50 1396 36.54 1277 37.09 474 42.32 189 38.18 118 47.97 
2010-2015 710 30.41 1318 34.50 1029 29.89 401 35.80 190 38.38 53 21.54 
Race 
White 1762 75.46 3075 80.50 2699 78.39 871 77.77 394 79.60 191 77.64 
Black 66 2.83 109 2.85 114 3.31 53 4.73 25 5.05 10 4.07 
Asian/Pacific 
Islander 
472 20.21 599 15.68 586 17.02 179 15.98 70 14.14 32 13.01 
Other 21 0.90 23 0.60 17 0.49 5 0.45 2 0.40 11 4.47 
Missing 14 0.60 14 0.37 27 0.78 12 1.07 4 0.81 2 0.81 
Ethnicity 
Hispanic 161 6.90 256 6.70 327 9.50 124 11.07 55 11.11 29 11.79 
Non-Hispanic 2155 92.29 3553 93.01 3104 90.15 995 88.84 439 88.69 206 83.74 
Missing 19 0.81 11 0.29 12 0.35 1 0.09 1 0.20 11 4.47 
Neighborhood socioeconomic status (SES)* 
Lowest quintile 104 4.45 158 4.14 151 4.39 62 5.54 40 8.08 25 10.16 
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Second quintile 188 8.05 298 7.80 313 9.09 122 10.89 64 12.93 29 11.79 
Third quintile 315 13.49 489 12.80 520 15.10 188 16.79 81 16.36 35 14.23 
Fourth quintile 468 20.04 735 19.24 666 19.34 230 20.54 105 21.21 46 18.70 
Highest 
quintile 
1202 51.48 2062 53.98 1737 50.45 496 44.29 195 39.39 106 43.09 
Missing 58 2.48 78 2.04 56 1.63 22 1.96 10 2.02 5 2.03 
Tumor receptor subtype** 
Estrogen (ER) 
and/or 
progesterone 
receptor (PR)-
positive and  
HER2-negative 
118 5.05 2336 61.15 1800 52.28 567 50.63 247 49.90 66 26.83 
HER2-positive 48 2.06 545 14.27 651 18.91 254 22.68 117 23.64 22 8.94 
Triple-negative 12 0.51 366 9.58 556 16.15 199 17.77 63 12.73 18 7.32 
Missing 2157 92.38 573 15.00 436 12.66 100 8.93 68 13.74 140 56.91 
Grade 
1 209 8.95 1199 31.39 470 13.65 120 10.71 21 4.24 31 12.60 
2 878 37.60 1551 40.60 1356 39.38 387 34.55 167 33.74 50 20.33 
3 865 37.04 820 21.47 1420 41.24 521 46.52 177 35.76 64 26.02 
Missing 383 16.40 250 6.54 197 5.72 92 8.21 130 26.26 101 41.06 
Histology 
Ductal 1989 85.18 3296 86.28 2919 84.78 923 82.41 413 83.43 168 68.29 
Lobular 181 7.75 283 7.41 341 9.90 174 15.54 56 11.31 12 4.88 
Other 165 7.07 241 6.31 183 5.32 23 2.05 26 5.25 66 26.83 
Marital Status 
Single 333 14.26 577 15.10 512 14.87 184 16.43 95 19.19 41 16.67 
Married 1577 67.54 2555 66.88 2322 67.44 747 66.70 289 58.38 122 49.59 
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Divorced 184 7.88 301 7.88 293 8.51 100 8.93 47 9.49 27 10.98 
Widowed 169 7.24 286 7.49 217 6.30 55 4.91 44 8.89 24 9.76 
Separated, 
Unmarried or 
Domestic 
Partner 
50 2.14 66 1.73 57 1.66 26 2.32 15 3.03 28 11.38 
Missing 22 0.94 35 0.92 42 1.22 8 0.71 5 1.01 4 1.63 
Payer 
Not insured 11 0.47 17 0.45 22 0.64 6 0.54 3 0.61 5 2.03 
Insurance, not 
otherwise 
specified 
244 10.45 367 9.61 362 10.51 111 9.91 45 9.09 20 8.13 
Managed 
care/HMO/PPO 
1455 62.31 2218 58.06 2031 58.99 658 58.75 241 48.69 111 45.12 
Medicaid 90 3.85 146 3.82 228 6.62 128 11.43 60 12.12 13 5.28 
Medicare 424 18.16 900 23.56 639 18.56 162 14.46 118 23.84 61 24.80 
Others 41 1.76 50 1.31 48 1.39 13 1.16 11 2.22 5 2.03 
Missing 70 3.00 122 3.19 113 3.28 42 3.75 17 3.43 31 12.60 
* Neighborhood socioeconomic status (SES) quintile was assigned based on a previously developed measurement by Yost et al 
for cases diagnosed from 2000-2005, and Shariff-Marco et al for cases diagnosed 2006-2015 (27,28). 
** Triple negative: estrogen receptor, progesterone receptor and HER2 all negative. HER2 positive: HER2 positive, regardless of 
estrogen receptor or progesterone receptor status.  
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Table 2. Metastatic Breast Cancer Term to Concept Mappings 
Custom Word Class Short Description Example Terms 
DRECUR Distant recurrence Recurrent metastatic tnbc, distant relapse, distant 
recurrences, distant metastatic disease involving 
LRECUR Local or regional recurrence Regional recurrence, nodal recurrence, loco-regional failure, 
locally recur, in-breast recurrence, local recur 
MBC Metastatic breast cancer Widespread metastatic breast cancer, widely metastatic 
triple, metastatic breast carcinoma, metastatic tnbc 
MBCLOW Metastatic breast cancer 
(low confidence) 
Metastic*, metasteses*, metastatis*, metastatic lobular 
carcinoma, metastatic lesion, metastatic lesions, metastatic 
foci, mbc, met brca 
METSBONE Metastatic disease to the 
bone 
Bone mets, bone metastasis, bone metasteses*, mets to 
spine, boney mets, diffuse skeletal mets, mets to spine 
METSBRAIN Metastatic disease to the 
brain 
Metastatic disease involving the brain, brain mets, mets to 
brain, brain metastasis, brain metastases 
METSLIVER Metastatic disease to the liver Liver mets, liver metastasis, liver metastases, hepatic mets, 
hepatic metastasis, hepatic metastases 
METSLUNG Metastatic disease to the lung Mets to lung, pulm mets, lung mets, mbc pulm, lung 
metastases 
METSNOS Metastatic disease (distant 
organ not specified) 
Widespread metastatic disease, stage4, newly diagnosed 
metastatic, stage iv 
RECUR Recurrence Recur, rapid recurrence, multiple recurrences, recurrent 
disease, reoccurrence, reoccurring 
DIED Death Passed away, expired on, deceased 
* these were original spellings from the clinical notes and the misspellings are left intentionally 
  
 21 
Table 3. Performance of Distant Labels and Classification Model Using 146 Manually Reviewed Gold Standard Patients 
Labels Source* Performance Measurements** 
AUC Sensitivity Specificity PPV NPV F-1 Score Accuracy 
Distant Labels  NA 0.889 0.797 0.810 0.881 0.848 0.842 
Classifier (CCR + EMR features) 0.925 0.861 0.878 0.873 0.867 0.867 0.870 
Classifier (CCR features only) 0.789 0.542 0.824 0.750 0.649 0.629 0.685 
*Distant Labels: natural language processing (NLP)-derived labels (using electronic medical records, EMR, only); Classifier (CCR + 
EMR features): recurrent metastatic breast cancer (MBC) classification (using NLP-derived and California Cancer Registry (CCR) 
features combined); Classifier (CCR features only): recurrent MBC classification (using CCR features only). 
** Note that positive predictive value (PPV), negative predictive value (NPV), F-1 score and overall accuracy are highly 
dependent on the prevalence of the condition, which in our case is 72/146 = 0.5. The actual prevalence of recurrent metastatic 
breast cancer in our study population is likely to be much lower. However, sensitivity, specificity, and area under the curve (AUC) 
are intrinsic properties of classifier and are insensitive to prevalence of cases (29,30). 
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Table 4. Case Detection Results by Metastatic Breast Cancer Status 
 
Recurrent MBC (Stage 0-III at 
diagnosis) Stage IV at diagnosis Non-MBC 
 No. % No. % No. % 
Total 1302 100 495 100 7590 100 
Age at diagnosis: mean(std) 52.99 (13.04) 54.61 (13.62) 55.36 (12.99) 
Year of breast cancer diagnosis 
Before 2005 526 40.40 116 23.43 1738 22.90 
2005-2009 463 35.56 189 38.18 2787 36.72 
2010-2015 313 24.04 190 38.38 3065 40.38 
Race  
White 1025 78.73 394 79.60 5887 77.56 
Black 51 3.92 25 5.05 229 3.02 
Asian/Pacific Islander 206 15.82 70 14.14 1371 18.06 
Other 4 0.31 2 0.40 57 0.75 
Missing 16 1.23 4 0.81 46 0.61 
Ethnicity 
Hispanic 129 9.91 55 11.11 588 7.75 
Non-Hispanic 1170 89.86 439 88.69 6968 91.81 
Missing 3 0.23 1 0.20 34 0.45 
Neighborhood socioeconomic status* 
Lowest quintile 45 3.46 40 8.08 342 4.51 
Second quintile 121 9.29 64 12.93 631 8.31 
Third quintile 215 16.51 81 16.36 988 13.02 
Fourth quintile 254 19.51 105 21.21 1433 18.88 
Highest quintile 646 49.62 195 39.39 4015 52.90 
Missing 21 1.61 10 2.02 181 2.39 
Stage  
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0 72 5.53 0 0.00 1813 23.87 
I 302 23.20 0 0.00 2837 37.37 
II 585 44.93 0 0.00 2186 28.80 
III 307 23.58 0 0.00 616 8.10 
IV 0 0.00 495 100.00 0 0.00 
Missing 36 2.76 0 0.00 141 1.86 
Tumor receptor subtype** 
Estrogen (ER) and/or 
progesterone receptor (PR)-
positive and HER2-negative 608 46.70 
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49.90 
3514 46.30 
HER2-positive 259 19.89 117 23.64 969 12.77 
Triple-negative 223 17.13 63 12.73 689 9.08 
Missing 212 16.28 68 13.74 2418 31.86 
Grade  
1 163 12.52 21 4.24 1511 19.91 
2 446 34.26 167 33.74 3020 39.79 
3 580 44.55 177 35.76 2400 31.62 
Missing 113 8.68 130 26.26 659 8.68 
Histology  
Ductal 1146 88.02 413 83.43 6433 84.76 
Lobular 117 8.99 56 11.31 703 9.26 
Other 39 3.00 26 5.25 454 5.98 
Marital Status  
Single 202 15.52 95 19.19 1133 14.93 
Married 865 66.44 289 58.38 5096 67.14 
Divorced 120 9.22 47 9.49 602 7.93 
Widowed 81 6.22 44 8.89 518 6.82 
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Separated, Unmarried or 
Domestic Partner 20 1.54 
15 3.03 
170 2.24 
Missing 14 1.07 5 1.01 71 0.94 
Payer  
Not insured 11 0.84 3 0.61 35 0.46 
Insurance, not otherwise specified 144 11.06 45 9.09 729 9.60 
Managed care/HMO/PPO 695 53.38 241 48.69 4489 59.14 
Medicaid 121 9.29 60 12.12 390 5.14 
Medicare 267 20.51 118 23.84 1610 21.21 
Others 21 1.61 11 2.22 115 1.52 
Missing 43 3.30 17 3.43 222 2.92 
* Neighborhood socioeconomic status (SES) quintile was assigned based on a previously developed measurement by Yost et al 
for cases diagnosed from 2000-2005, and Shariff-Marco et al for cases diagnosed 2006-2015 (27,28). 
** Triple negative: estrogen receptor, progesterone receptor and HER2 all negative. HER2 positive: HER2 positive, regardless of 
estrogen receptor or progesterone receptor status. 
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Figures
 
Figure 1. Flowchart of Oncoshare Patient Count by Step. SHC: Stanford Health Care; PAMF: Palo Alto Medical Foundation; MBC; 
metastatic breast cancer. 
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Figure 2. Receiver Operating Characteristic Curve (ROC) of Statistical Classifiers Evaluated using the Test Set of 146 Patients. The 
area under the curve (AUC) of classifier with CCR and EMR features is 0.925 with 95% confidence interval 0.880-0.969. The AUC 
of the classifier with CCR features only is 0.789 with 95% confidence interval 0.716-0.861. 
  
1−Specificity
Se
ns
itiv
ity
1.0 0.8 0.6 0.4 0.2 0.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Classifier (CCR + EMR features)
Classifier (CCR features only)
 27 
Acknowledgements 
The authors gratefully acknowledge research support from the Breast Cancer Research 
Foundation; the Suzanne Pride Bryan Fund for Breast Cancer Research; the BRCA Foundation; 
the Jan Weimer Junior Faculty Chair in Breast Oncology; the Susan and Richard Levy Gift Fund; 
the Regents of the University of California’s California Breast Cancer Research Program (16OB-
0149 and 19IB-0124); and the National Cancer Institute’s Surveillance, Epidemiology and End 
Results Program under contract HHSN261201000140C awarded to the Cancer Prevention 
Institute of California. The collection of cancer incidence data used in this study was supported 
by the California Department of Health Services as part of the statewide cancer reporting 
program mandated by California Health and Safety Code Section 103885; the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results Program under contract 
HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract 
HHSN261201000035C awarded to the University of Southern California, and contract  
HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease 
Control and Prevention’s National Program of Cancer Registries, under agreement #1U58 
DP000807-01 awarded to the Public Health Institute. JLC was supported by an ASCO Young 
Investigator Award from the Conquer Cancer Foundation. AYL acknowledges Stanford Graduate 
Fellowship. The ideas and opinions expressed herein are those of the authors, and 
endorsement by the University or State of California, the California Department of Health 
Services, the National Cancer Institute, or the Centers for Disease Control and Prevention or 
their contractors and subcontractors is not intended nor should be inferred. 
  
 28 
References 
1.  American Cancer Society. Breast Cancer Facts & Figures 2017-2018 [Internet]. 
Cancer.org. 2017 [cited 2018 Feb 14]. p. 1–44. Available from: 
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-
statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf 
2.  Berry D a, Cronin K a, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening 
and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–
92.  
3.  Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of 
Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US 
Women, 2000-2012. Jama. 2018;319(2):154.  
4.  Warren JL, Yabroff KR. Challenges and Opportunities in Measuring Cancer Recurrence in 
the United States. J Natl Cancer Inst. 2015;107(8).  
5.  Howlader N, Chen VW, Ries LAG, Loch MM, Lee R, DeSantis C, et al. Overview of breast 
cancer collaborative stage data items-their definitions, quality, usage, and clinical 
implications: A review of seer data for 2004-2010. Vol. 120, Cancer. 2014. p. 3771–80.  
6.  Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of 
Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol 
Biomarkers Prev. 2017;26(6):809–15.  
7.  Nordstrom BL, Simeone JC, Malley KG, Fraeman KH, Klippel Z, Durst M, et al. Validation 
of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-
small Cell Lung, and Colorectal Cancer. Front Oncol. 2016;6(February):1–9.  
8.  Nordstrom BL, Whyte JL, Stolar M, Mercaldi C, Kallich JD. Identification of metastatic 
cancer in claims data. Pharmacoepidemiol Drug Saf. 2012;21(SUPPL.2):21–8.  
9.  Whyte JL, Engel-Nitz NM, Teitelbaum A, Gomez Rey G, Kallich JD. An evaluation of 
algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative 
claims data. Med Care. 2015;53(7):e49–57.  
10.  Hassett MJ, Ritzwoller DP, Taback N, Cronin AM, Ting G V, Schrag D, et al. Validating 
Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer 
Recurrence using Two Large Contemporary Cohorts. Med Care. 2015;52(10):1–17.  
11.  Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, et al. Administrative data 
algorithms to identify second breast cancer events following early-stage invasive breast 
cancer. J Natl Cancer Inst. 2012;104(12):931–40.  
12.  Carrell DS, Halgrim S, Tran DT, Buist DSM, Chubak J, Chapman WW, et al. Using natural 
language processing to improve efficiency of manual chart abstraction in research: The 
case of breast cancer recurrence. Am J Epidemiol. 2014;179(6):749–58.  
13.  Strauss JA, Chao CR, Kwan ML, Ahmed SA, Schottinger JE, Quinn VP. Identifying primary 
and recurrent cancers using a SAS-based natural language processing algorithm. J Am 
Med Informatics Assoc. 2013;20(2):349–55.  
14.  Craven M, Kumlien J. Constructing biological knowledge bases by extracting information 
from text sources. Proc Int Conf Intell Syst Mol Biol. 1999;77–86.  
15.  Mintz M, Bills S, Snow R, Jurafsky D. Distant supervision for relation extraction without 
 29 
labeled data. In: Proceedings of the Joint Conference of the 47th Annual Meeting of the 
ACL and the 4th International Joint Conference on Natural Language Processing of the 
AFNLP: Volume 2 - ACL-IJCNLP ’09. 2009. p. 1003.  
16.  Ratner A, De Sa C, Wu S, Selsam D, Ré C. Data Programming: Creating Large Training Sets, 
Quickly. NIPS Proc. 2016;3567–75.  
17.  Weber SC, Seto T, Olson C, Kenkare P, Kurian AW, Das AK. Oncoshare: lessons learned 
from building an integrated multi-institutional database for comparative effectiveness 
research. AMIA Annu Symp Proc. 2012;2012:970–8.  
18.  Thompson CA, Kurian AW, Luft HS. Linking electronic health records to better understand 
breast cancer patient pathways within and between two health systems. EGEMS 
(Washington, DC). 2015;3(1):1127.  
19.  Tamang SR, Hernandez-Boussard T, Ross EG, Patel M, Gaskin G, Shah N. Enhanced 
Quality Measurement Event Detection: An Application to Physician Reporting. eGEMs 
(Generating Evid Methods to Improv patient outcomes). 2017 May 30;5(1):5.  
20.  Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical 
terminology. Nucleic Acids Res. 2004;32(90001):267D–270.  
21.  Tseytlin E, Mitchell K, Legowski E, Corrigan J, Chavan G, Jacobson RS. NOBLE - Flexible 
concept recognition for large-scale biomedical natural language processing. BMC 
Bioinformatics. 2016;  
22.  Aronson AR, Lang F-M. An overview of MetaMap: historical perspective and recent 
advances. J Am Med Inform Assoc. 2010;  
23.  Friedman J, Hastie T, Tibshirani R, Simon N, Friedman J, Hastie T, et al. Regularization 
Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;39(1):1–
22.  
24.  Friedman J, Hastie T, Tibshirani R. The elements of statistical learning. Vol. 1. Springer 
series in statistics New York, NY, USA:; 2001.  
25.  Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source 
package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 
2011;12(1):77.  
26.  California Department of Public Health. California Cancer Registry [Internet]. [cited 2018 
Oct 13]. Available from: 
http://www.ccrcal.org/Data_and_Statistics/Cancer_Data_for_Research.shtml 
27.  Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer 
incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;  
28.  Shariff-Marco S, Yang J, John EM, Kurian AW, Cheng I, Leung R, et al. Intersection of 
Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. J Community 
Health. 2015;  
29.  Pepe MS. The statistical evaluation of medical tests for classification and prediction. 
Medicine; 2003.  
30.  Zhou X-H, McClish DK, Obuchowski NA. Statistical methods in diagnostic medicine. Vol. 
569. John Wiley & Sons; 2009.  
 
  
 30 
Appendix 
Supplemental Table S1. Length of follow-up in days by survival status and tumor stage at initial diagnosis in Stanford Health 
Care patients. Survival status was collected by California Cancer Registry as of 2014-12-31 or any later follow-up of the specific 
patient.  Last follow-up date was the latest date of the last follow-up from California Cancer Registry, 2014-12-31 and last 
encounter date in Stanford Health Care’ electronic medical record. 
 Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Missing Total 
Alive n 2162 3351 2668 695 129 172 9177 
min 243 190 282 401 241 393 190 
max 5932 6053 6083 5778 5614 5921 6083 
mean 2893 2847 2887 2547 2200 2957 2840 
sd 1343.06 1432.91 1421.03 1268.84 1258.82 1368.73 1397.83 
Dead n 168 468 771 423 360 74 2264 
min 562 563 261 459 348 502 261 
max 5684 5748 5692 5466 5468 5470 5748 
mean 3530 3543 3631 2928 2770 3414 3330 
sd 1247.06 1289.64 1268.87 1273.46 1391.04 1224.44 1336.85 
Missing n 5 1 4 2 6 0 18 
min 1094 4971 523 464 560 NA 464.0 
max 4182 4971 5222 1379 3973 NA 5222.0 
mean 2577 4971 2351 921.5 1356 NA 2069.0 
sd 1433.99 NA 2043.13 647.00 1308.64 NA 1634.97 
Total n 2335 3820 3443 1120 495 246 11459 
min 243 190 261 401 241 393 190 
max 5932 6053 6083 5778 5614 5921 6083 
mean 2938 2933 3053 2688 2604 3094 2935 
sd 1346.22 1434.45 1423.14 1284.59 1384.07 1341.04 1400.37 
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Supplemental Table S2. Length of Follow-up in days by Survival Status and Insurance Status in Stanford Health Care patients 
 Insured* Not Insured Others/Missing Total 
Alive n 8691 40 446 9177 
min 190 641 365 190 
max 6083 5622 5978 6083 
mean 2815 2935 3301 2840 
sd 1393.37 1376.43 1409.20 1397.83 
Dead n 2125 24 115 2264 
min 261 1456 714 261 
max 5748 5403 5464 5748 
mean 3313 3863 3534 3330 
sd 1337.65 1136.35 1330.85 1336.85 
Missing n 16 0 2 18 
min 464 NA 778 464.0 
max 5222 NA 1094 5222.0 
mean 2210 NA 936 2069.0 
sd 1683.36 NA 223.45 1634.97 
Total n 10832 64 563 11459 
min 190 641 365 190 
max 6083 5622 5978 6083 
mean 2912 3283 3340 2935 
sd 1397.23 1359.90 1400.46 1400.37 
*Insured: Insurance, NOS, Managed care/HMO/PPO, Medicaid, and Medicare 
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Supplemental Table 3.  Top Classification Features by Data Source and Relative Rank 
Rank Source Data Field Regression 
Coefficient 
Exponential of 
Regression Coefficient 
1 Electronic Medical 
Record (EMR) 
Clinical Notes 
MBCuniPN (Number of unique mentions of 
terms in MBC class) 
3.211 24.797 
2 EMR Clinical Notes METSNOSPosCyto (Number of positive 
metastatic mentions in cytology notes) 
0.994 2.701 
3 EMR Clinical Notes MBCPosOutSR (Number of positive MBC 
mentions in outpatient screen review notes) 
0.818 2.266 
4 EMR Clinical Notes LRECURPosOutSR (Number of positive loco-
regional recurrence mentions in outpatient 
screen review notes) 
0.746 2.109 
5 EMR Clinical Notes LRECURPosMNR (Number of positive loco-
regional recurrence mentions in magnetic 
nuclear resonance notes) 
0.677 1.968 
11* California Cancer 
Registry (CCR) 
Stage 3 (reference level Stage 0) 0.379 1.461 
24 CCR Payer Not Insured (reference level missing 
insurance status) 
0.177 1.194 
28 CCR Stage 2 (reference level Stage 0) 0.153 1.166 
29 CCR Diagnosis Before 2005 (reference level 
diagnosis year 2005-2009) 
0.149 1.161 
40 CCR Triple Negative (reference level Estrogen 
(ER) and/or progesterone receptor (PR)-
positive and HER2-negative) 
0.119 1.126 
42 CCR Socioeconomic status 3rd quintile (reference 
level 1st quintile) 
0.113 1.119 
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* For example, the odds of having recurrent metastatic breast cancer (MBC) for patients with Stage 3 at diagnosis are 46.1% 
higher than that of Stage 0, holding all other features constant. 
** Since mentions of words from these four word classes “METSBONE”, “METSBRAIN”, “METSLIVER”, and “METSLUNG” were 
used to determine the distand labels, none of the input features into the classifier used information regarding to features in 
these four word classes. 
*** Compared to logistic regression models without regularization, interpretation of these coefficients needs to be proceeded 
with caution, as L2 regularization reduces the regression coefficients of correlated variables.  
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Supplemental Figure S4. Corpus-driven Expansion of Metastatic Breast Cancer Seed Terms Using Word and Phrase Embeddings 
 
Supplemental Figure S5. Example Text Snippet Processed by CLEVER To Extract Information On Metastatic Disease 
 
 
